Cigna Healthcare Medicare Advantage Coverage Policy Development and Application - (A018) | CIGNA Coverage Update

Cigna Healthcare modified policy A018 (ad_a018_medicare_advantage_cp_development_application), effective September 26, 2025, clarifying when Cigna's internal coverage policies can substitute for missing Medicare criteria in Medicare Advantage determinations — directly affecting medical necessity decisions for CPT codes including 64624, 81418, 81443, 81490, 81525, 81540, and 81554.

This update matters if your team bills any of those seven codes to Cigna Medicare Advantage plans. When no National Coverage Determination (NCD) or Local Coverage Determination (LCD) fully defines coverage criteria, Cigna Healthcare will now apply its own internal coverage policy standards to determine whether a service is reasonable and necessary. The affected codes span genicular nerve destruction, pharmacogenomics panels, genetic testing, autoimmune biomarker analysis, and oncology gene expression profiling — a broad mix that touches oncology, rheumatology, pulmonology, and pain management billing.

Quick-Reference Table

Cigna Medicare Advantage Coverage Policy A018: Medical Necessity Criteria and How They Apply in 2025

Here's the core issue this policy addresses: Medicare's NCD and LCD framework doesn't cover everything. There are gaps — services where CMS hasn't issued a national or local determination. For Medicare Advantage plans, that gap creates a question: what standard does the payer use to decide if a service is reasonable and necessary?

Policy A018 answers that question for Cigna Healthcare. When an NCD, LCD, or Medicare statute doesn't fully establish coverage criteria, Cigna applies the criteria from its own internal coverage policies. Those policies describe their coverage standards using terms like "Not Covered or Reimbursable" — language Cigna uses in its commercial insurance business.

This is where billing teams get tripped up. Those terms reflect commercial benefit determination language. But Cigna's position is that the underlying criteria are still valid for Medicare Advantage medical necessity decisions because they're built on scientific evidence and current clinical practice guidelines. That's their argument for why the standard holds across product lines.

The practical effect: for the seven CPT codes listed in this policy, your team can't rely on the absence of an NCD or LCD as a green light. Cigna will apply its own coverage policy criteria to determine medical necessity. If those criteria aren't met, you'll get a claim denial regardless of whether Medicare itself has published a definitive coverage rule.

Prior authorization requirements under Cigna Medicare Advantage plans remain plan-specific, but this policy sets the evidentiary floor for what Cigna considers reasonable and necessary when authorizing or adjudicating these services. Check plan documents for specific prior auth requirements tied to each code.

Coverage Indications at a Glance

This policy doesn't list specific covered or non-covered indications the way a standard clinical coverage policy does. Instead, it establishes a meta-rule: Cigna's internal coverage policy criteria apply to Medicare Advantage determinations when NCD/LCD coverage criteria are absent or incomplete.

The seven CPT codes listed are the specific services subject to this framework. For each, Cigna's internal coverage policy — not just Medicare's NCD/LCD — defines what qualifies as reasonable and necessary.

Cigna Medicare Advantage Billing Guidelines and Action Items for 2025

1. Pull Cigna's Internal Coverage Policies for All Seven CPT Codes — Now

Don't wait until you have a denied claim to find out what Cigna's criteria say. The effective date of September 26, 2025 is already here. Go to Cigna's coverage policy library and locate the specific policy governing each of these codes. For genomics codes like 81418, 81443, 81490, 81525, 81540, and 81554, Cigna's internal standards are often more restrictive than what you might expect from the absence of an NCD.

2. Stop Treating LCD/NCD Gaps as Coverage Confirmation

This is the single biggest billing mistake this policy is designed to clarify. If your team's workflow says "no NCD or LCD means bill it," that logic fails for Cigna Medicare Advantage. Policy A018 explicitly closes that gap. Cigna's own coverage policy fills it. Retrain your billing team on this distinction before the next claim cycle.

3. Audit Open and Pending Claims for These CPT Codes

Run a targeted audit on any Medicare Advantage claims for CPT 64624, 81418, 81443, 81490, 81525, 81540, and 81554 that are open, pending, or recently denied. For denials on or after September 26, 2025, check whether the denial reason references Cigna's internal coverage policy criteria. That's a signal the A018 framework is in play.

4. Tighten Clinical Documentation for Genomics and Gene Expression Codes

Cigna's internal coverage policies for genomic panels — especially pharmacogenomics (81418) and oncology panels (81525, 81540) — require specific clinical justification. For 81525 (colon cancer mRNA panel), document the stage, treatment decision context, and why the panel results will change management. For 81554 (IPF gene expression), confirm the IPF diagnosis is documented with appropriate supporting workup. Generic "ordered by physician" documentation won't survive a Cigna medical necessity review.

5. Verify Prior Authorization Requirements Separately for Each Plan

Policy A018 sets the medical necessity standard, but prior authorization requirements vary by Cigna Medicare Advantage plan. For genicular nerve destruction (64624) and high-cost genomics panels, prior auth is common. Check the specific plan's authorization requirements before submitting. A clean claim that lacks required prior auth is still a denied claim.

6. Flag 81490 (Autoimmune Biomarker Panel) for RA Billing Reviews

CPT 81490 is the 12-biomarker immunoassay for rheumatoid arthritis. Cigna's coverage criteria for this code have historically required that the diagnosis remain uncertain after standard workup. If your rheumatology billing team is submitting 81490 for established RA patients, that's a high-risk claim pattern under Cigna's criteria. Review your documentation standards now.

7. Talk to Your Compliance Officer Before Appealing A018-Based Denials

If you receive a denial that cites Cigna's internal coverage policy criteria under the A018 framework, the appeals path is different from a standard LCD non-coverage denial. Your compliance officer should review the appeal strategy. Arguing that "Medicare doesn't have an NCD for this" is not a winning argument here — Cigna has explicitly stated that their criteria apply in exactly that situation.

CPT Codes Under Cigna Policy A018 (ad_a018_medicare_advantage_cp_development_application)

CPT Codes Subject to Cigna Internal Coverage Policy Criteria

These are the codes explicitly listed in policy A018. Cigna Healthcare applies its internal coverage policy standards to these codes for Medicare Advantage determinations when NCD or LCD criteria do not fully establish coverage.

No ICD-10-CM codes are listed in the policy data for A018. Diagnosis code requirements are governed by the individual coverage policies that apply to each CPT code listed above.

What This Policy Really Means for Your Revenue Cycle

The real issue here isn't administrative. It's financial exposure across a set of high-value codes.

Oncology gene expression panels like 81540 (tumor of unknown origin, 92-gene panel) and 81525 (colon mRNA panel) carry significant reimbursement. A single denial on 81540 can represent thousands of dollars. If your team hasn't mapped out Cigna's internal coverage policy criteria for these codes — separate from NCD/LCD — you're billing blind.

The same logic applies to 81554 for idiopathic pulmonary fibrosis. IPF gene expression testing is expensive, documentation-intensive, and increasingly scrutinized. Cigna's internal criteria for IPF-related testing require clear evidence that the diagnosis was established through appropriate clinical workup before ordering the panel.

For pain management billing around 64624 (genicular nerve destruction), Cigna has issued specific criteria around prior conservative treatment failure and imaging findings. That policy applies to your Medicare Advantage patients under A018. Make sure your pain management colleagues know that.

Cigna Healthcare's position in this policy is legally defensible — Medicare Advantage plans are explicitly permitted to apply clinical coverage policies in gaps not addressed by NCD or LCD. The CMS framework for Medicare Advantage allows this. The billing reality is that your team needs to operate as if Cigna's commercial-style criteria apply to your Medicare Advantage patients for these seven codes.

If you're billing in multiple Cigna Medicare Advantage markets, remember that individual plan-level coverage policies can layer on top of A018. A national policy sets the floor; plan documents may add requirements. This is the same pattern you see with other Cigna Medicare Advantage policies — the A018 framework is consistent with how Cigna has structured its MA coverage policies across its product line.